Table 1.

Baseline Patient Demographic and Clinical Characteristics

	N = 45
Age (years)
Median	69
(Range)	(51–86)
Race
Caucasian	39 (86.7%)
African-American	4 (8.9%)
Asian	1 (2.2%)
Hispanic	1 (2.2%)
Baseline PSA (ng/mL)
Median	57.6
(Range)	(5.4-457)
Gleason Sum
≤ 7	11 (24.4%)
8	8 (17.8%)
9	18 (40.0%)
10	5 (11.1%)
Unknown	3 (6.7%)
Visceral Disease
Yes	7 (15.6%)
No	38 (84.4%)
Lines of Prior Novel AR Targeted Therapy
1	21 (46.7%)
≥2	24 (53.3%)
Prior Taxane Chemotherapy
Yes	20 (44.4%)
No	25 (55.6%)
≥ 2 Novel AR Targeted Therapy AND Prior Taxane Chemotherapy
Yes	15 (33.3%)
No	30 (66.7%)

N Number of Patients, AR Androgen Receptor, PSA Prostate-specific antigen